ACAD241220C28000
- 0.00
- 0.000.00%
ACADIA Pharmaceuticals Newsroom
Express News | ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Express News | ACADIA Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
Why Acadia Pharmaceuticals (ACAD) Is a Top Momentum Stock for the Long-Term
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
Baird Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $28
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
JMP Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $39
JMP Securities Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
Acadia Signs Licensing Deal for Essential Tremor Drug Candidate
Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711; Under The Terms Of The License Agreement, Saniona Will Receive $28M Upfront Plus Potential Milestone Payments Of Up To $582M
Express News | ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones
Express News | ACADIA Pharmaceuticals Inc - to Initiate Phase 2 Study of San711 in 2026
Express News | ACADIA Pharmaceuticals Announces Exclusive License Agreement With Saniona for San711
Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona for SAN711
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $32
ACADIA Pharmaceuticals: Strategic Leadership and Growth Prospects Support Buy Rating
Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure